Drug profile · INN
gefapixant citrate
LYFNUA
gefapixant citrate (LYFNUA) is a p2x purinoceptor 3 antagonist.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — gefapixant citrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
gefapixant citrate (LYFNUA) is a p2x purinoceptor 3 antagonist.
Key facts
INN gefapixant citrate
Brand LYFNUA
Mechanism P2X purinoceptor 3 antagonist
Target P2X purinoceptor 3
Mechanism of action
P2X purinoceptor 3 antagonist
Primary target: P2X purinoceptor 3
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is gefapixant citrate?
gefapixant citrate (LYFNUA) is a p2x purinoceptor 3 antagonist.
What is the brand name for gefapixant citrate?
LYFNUA is a marketed brand name for gefapixant citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.